Cargando...
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease
OBJECTIVES: To investigate whether sildenafil citrate, a selective phosphodiesterase type 5 inhibitor, may improve endothelial vasomotor and fibrinolytic function in patients with coronary heart disease. DESIGN: Randomised double blind placebo controlled crossover study. PATIENTS AND METHODS: 16 mal...
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMJ Group
2006
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1860771/ https://ncbi.nlm.nih.gov/pubmed/15863522 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/hrt.2004.059683 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|